Raspa participated in CPHI Milan 2026, held from 6 to 8 October at Fiera Milano, Italy. Organised by Informa Markets, CPHI is one of the world’s largest pharmaceutical events, bringing together companies across the pharmaceutical value chain, from APIs, excipients, and fine chemicals to finished dosage forms, contract services, machinery, and packaging. For Raspa, the event marked an important milestone in its engagement with the global pharmaceutical industry. Over three days, the team met pharmaceutical companies, industry leaders, and potential partners to exchange perspectives on evolving industry priorities and explore areas for collaboration.

Key Industry Priorities in Focus

Discussions at the exhibition consistently returned to the factors that matter most to companies sourcing complex active pharmaceutical ingredients (APIs):

• Consistent product quality: reliable, batch-to-batch quality as a baseline expectation for API suppliers
• Supply chain reliability: secure, dependable supply that reduces sourcing risk
• Scalable manufacturing: the ability to move efficiently from development to commercial volumes
• Collaboration: long-term partnerships to manage the complexity of advanced API development

These conversations also shed light on market expectations and opportunities for innovation in fermentation-based API manufacturing, an area in which Raspa is building specialised capabilities.

Leadership Perspectives

Padmakshi Agarwal, Co-Founder and CEO of Raspa, said:

“At Raspa, our goal is to become a trusted global partner for complex fermentation-based APIs, combining scientific depth with the consistency and scale the industry needs. At CPHI Milan, partners repeatedly emphasised quality, reliable supply, and scalability: the very strengths we are building. This reinforces our confidence in the path we have chosen. We are excited about the road ahead and about the role Raspa will play in shaping the future of API manufacturing.”

Ram Agarwal, Co-Founder and CFO of Raspa, said:

“Building a strong presence in the global pharmaceutical ecosystem requires reliable partnerships, a clear understanding of market requirements, and a long-term approach to developing sustainable manufacturing operations. Our interactions at CPHI Milan offered valuable perspectives on these priorities and revealed opportunities for future collaboration.”

Looking Ahead

The insights gained in Milan will inform Raspa’s continued efforts to develop its capabilities in complex fermentation-based APIs and to establish meaningful, long-term partnerships. Raspa looks forward to building on the connections made at CPHI Milan 2026 and helping advance pharmaceutical manufacturing through specialised expertise, process innovation, and a commitment to quality.